These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 25200487)

  • 41. Theory and practice of pharmacopoeial control of quality of drugs and excipients X. Number of parallel determinations, processing of results and their use in the assessment of the content of active substances and excipients in the European Pharmacopoeia (Ph. Eur.).
    Šubert J; Kolář J
    Ceska Slov Farm; 2019; 68(4):157-160. PubMed ID: 31822108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The "challenge test" in the European pharmacopoeia].
    Boll Chim Farm; 1991; 130(7):283-4. PubMed ID: 1756013
    [No Abstract]   [Full Text] [Related]  

  • 43. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The harmonization of the regulation of blood products: a European perspective.
    Seitz R; Heiden M; Nübling CM; Unger G; Löwer J
    Vox Sang; 2008 May; 94(4):267-76. PubMed ID: 18179678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Working methods of the European Pharmacopoeia (author's transl)].
    Stainier C
    J Pharm Belg; 1975; 30(5-6):425-31. PubMed ID: 1214201
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug safety in the European community.
    Sauer F
    Drug Saf; 1990; 5 Suppl 1():141-8. PubMed ID: 2182057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1133-8. PubMed ID: 25123139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Commentaries on the monographs of Group 10 in Volumes I and II of the European Pharmacopoeia].
    Bosly J; De Moerloose P
    J Pharm Belg; 1975; 30(5-6):549-77. PubMed ID: 1214208
    [No Abstract]   [Full Text] [Related]  

  • 50. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Role of the Pharmacopoeia Committee of the Ministry of Public Health of the USSR in improving drug preparation quality].
    Oboĭmakova OM
    Farm Zh; 1977; 32(4):28-31. PubMed ID: 913542
    [No Abstract]   [Full Text] [Related]  

  • 54. [Chromatographic methods in the European Pharmacopoeia].
    Ráfliné RZ; Kószeginé SH; Török I; Paál T
    Acta Pharm Hung; 2001 Aug; 71(2):205-12. PubMed ID: 11862671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The "responsible pharmacist" in Europe: is there a French exception?].
    Chalchat B
    Ann Pharm Fr; 2002 Sep; 60(5):352-5. PubMed ID: 12378147
    [No Abstract]   [Full Text] [Related]  

  • 57. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; Annex 6 on Uniformity of Dosage Units General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(115):34314-5. PubMed ID: 25011159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microbial limits reviewed: the basis for unique Australian regulatory requirements for microbial quality of non-sterile pharmaceuticals.
    Tang S
    PDA J Pharm Sci Technol; 1998; 52(3):100-9. PubMed ID: 9691672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Reduction of animal experiments in experimental drug testing].
    Behrensdorf-Nicol H; Krämer B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1173-80. PubMed ID: 25183445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.